Although proton pump inhibitors may reduce heartburn and gastrointestinal bleeding in hospital patients, the therapy may also raise their mortality risk, according to a recent study published in the ...

Objective: To systematically review studies qualitatively to compare the risks (gastrointestinal [GI] and cardiovascular) and benefits (pain control) of cyclooxygenase-2 inhibitors (coxibs) relative ...

The most widely used H. pylori treatments are 1-week triple therapy regimens involving twice daily dosing with a PPI, clarithromycin 500 mg and either amoxicillin 1 g or metronidazole 400−500 mg.

Sources of error that may lead to false association include PPI use shortly before diagnosis, short-term PPI use.

Proton pump inhibitors are among the most commonly prescribed medications worldwide, but concerns about a possible link to ...

PPIs reduce gastric ulters (shown) but may weaken bones Taking PPIs for several years can significantly raise the risk of osteoporosis-related fracture. Researchers have good news and bad news for ...

Another option is to replace a nonselective NSAID with a COX-2 inhibitor, a selective NSAID that is associated with a decreased incidence of ulcers. 1,12,13 The mucosal protective agent misoprostol ...

Please provide your email address to receive an email when new articles are posted on . Incidence of 30-day rebleeding was 7.1% in the vonoprazan group and 10.4% in the proton pump inhibitor group.

Long-term use of proton pump inhibitor medication does not appear to be associated with an increased risk of stomach cancer.

The long term use of proton pump inhibitors (PPIs), a class of drugs widely used to treat acid reflux and ulcers, may not be linked to any increased risk of developing gastric (stomach) cancer, finds ...